Sinopia Biosciences scores NIH grant to supercharge AI-driven drug discovery

The funding will accelerate Sinopia’s data-driven drug discovery efforts

Sinopia Biosciences, a biotech company pioneering next-generation therapeutics through its proprietary LEADS drug discovery platform, has announced it has received a research grant from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH).  

The funding will accelerate Sinopia’s data-driven drug discovery efforts. 

LEADS harnesses system-level omics data to redefine how cellular phenotypes are understood. Instead of relying on a handful of markers, the platform analyzes hundreds of thousands of cellular features, enabling unbiased discovery and deep mechanistic insight. To date, Sinopia has built the largest metabolomics dataset characterizing a small-molecule library. 

The NIGMS grant will fund the next phase of platform development, focusing on integrating computation and experimentation to expand metabolomic profiling of small-molecule libraries.  

Phase I will create novel deep learning algorithms to broaden coverage of chemical and biological space while reducing experimental demands. Ultimately, the platform aims to scale efficiently across vastly larger numbers of compounds, cell lines, and systems, the company has said. 

“We are grateful to NIGMS for their support,” said Aarash Bordbar, co-founder and Chief Technology Officer of Sinopia Biosciences. “This non-dilutive funding enables continued development of the LEADS platform as we continue to advance our internal programs and pursue our mission to transform treatment of complex diseases.”